Literature DB >> 22077199

Interictal type 1 cannabinoid receptor binding is increased in female migraine patients.

Bart J Van der Schueren1, Koen Van Laere, Nathalie Gérard, Guy Bormans, Jan N De Hoon.   

Abstract

OBJECTIVE: To compare binding of the type 1 cannabinoid receptor (CB1R) between migraine patients and healthy volunteers.
BACKGROUND: It has been suggested that endocannabinoid deficiency may play a role in the pathophysiology of migraine. Nonetheless, biochemical studies substantiating this idea remain scarce and are faced with methodological shortcomings partly because of the difficulty to perform measurements of endocannabinoids within the central nervous system itself.
METHODS: An observational cross-sectional study was conducted in 20 female migraine patients and 18 healthy women matched for age and body mass index. Positron emission tomography acquisition was performed 90 minutes after intravenous injection of the radioligand [(18)F]MK-9470 to assess binding of [(18)F]MK-9470 to CB1R.
RESULTS: Binding of CB1 R was globally increased in migraine patients vs healthy controls (average gray matter difference +16%; P = .009, 2-sample 2-sided Student's t-test). There were no correlations between CB1R binding and any predefined migraine characteristics. Increases in CB1R binding were most pronounced in the anterior cingulate, mesial temporal, prefrontal, and superior frontal cortices.
CONCLUSION: The increased interictal CB1R binding, especially in brain regions that exert top-down influences to modulate pain, supports the idea that endocannibinoid deficiency is present in female patients suffering from episodic migraine.
© 2011 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077199     DOI: 10.1111/j.1526-4610.2011.02030.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  9 in total

1.  Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences.

Authors:  Marc D Normandin; Ming-Qiang Zheng; Kuo-Shyan Lin; N Scott Mason; Shu-Fei Lin; Jim Ropchan; David Labaree; Shannan Henry; Wendol A Williams; Richard E Carson; Alexander Neumeister; Yiyun Huang
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-01       Impact factor: 6.200

Review 2.  Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.

Authors:  Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

Review 3.  Does exercise make migraines worse and tension type headaches better?

Authors:  Nada Ahmad Hindiyeh; John Claude Krusz; Robert Paul Cowan
Journal:  Curr Pain Headache Rep       Date:  2013-12

Review 4.  Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.

Authors:  Lu Hou; Jian Rong; Ahmed Haider; Daisuke Ogasawara; Cassis Varlow; Michael A Schafroth; Linjing Mu; Jiefeng Gan; Hao Xu; Christopher J Fowler; Ming-Rong Zhang; Neil Vasdev; Simon Ametamey; Benjamin F Cravatt; Lu Wang; Steven H Liang
Journal:  J Med Chem       Date:  2020-12-30       Impact factor: 7.446

5.  Variants in the CNR1 gene predispose to headache with nausea in the presence of life stress.

Authors:  G Juhasz; E Csepany; M Magyar; A E Edes; N Eszlari; G Hullam; P Antal; G Kokonyei; I M Anderson; J F W Deakin; G Bagdy
Journal:  Genes Brain Behav       Date:  2016-11-23       Impact factor: 3.449

Review 6.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

Review 7.  Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.

Authors:  Matthew E Sloan; Caroline W Grant; Joshua L Gowin; Vijay A Ramchandani; Bernard Le Foll
Journal:  Acta Pharmacol Sin       Date:  2018-08-30       Impact factor: 6.150

Review 8.  Endocannabinoid System and Migraine Pain: An Update.

Authors:  Rosaria Greco; Chiara Demartini; Anna M Zanaboni; Daniele Piomelli; Cristina Tassorelli
Journal:  Front Neurosci       Date:  2018-03-19       Impact factor: 4.677

Review 9.  Clinical Evidence of Cannabinoids in Migraine: A Narrative Review.

Authors:  Flavia Lo Castro; Carlo Baraldi; Lanfranco Pellesi; Simona Guerzoni
Journal:  J Clin Med       Date:  2022-03-08       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.